Cell
Volume 170, Issue 1, 29 June 2017, Page 5
Journal home page for Cell

Bench to Bedside
Splicing-Correcting Therapy for SMA

https://doi.org/10.1016/j.cell.2017.06.028Get rights and content
Under an Elsevier user license
open archive

Spinal muscular atrophy (SMA) is caused by deficiency of SMN protein, which is crucial for spliceosome subunits biogenesis. Most SMA patients have SMN1 deletions, leaving SMN2 as sole SMN source; however, a C→T substitution converts an exonic-splicing enhancer (ESE) to a silencer (ESS), causing frequent exon7 skipping in SMN2 pre-mRNA and yielding a truncated protein. Antisense treatment to SMN2 intron7-splicing silencer (ISS) improves SMN expression and motor function. To view this Bench to Bedside, open or download the PDF.

Cited by (0)